Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	7/11/2007 1:09:42 PM
	Read Replies (1) of 946

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results 13:01 EDT Wednesday, July 11, 2007 SEATTLE, July 11 /PRNewswire-FirstCall/ -- On Wednesday, July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European Time members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTAX: CTIC) management team will host a conference call to discuss today's announcement of the interim results of its phase II/III RAPID trial comparing CHOP-R to CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R, in first-line treatment of patients with aggressive non-Hodgkin's lymphoma. Conference Call Numbers Wednesday, July 11 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m. Central European 1-800-240-7305 (US Participants) 1-303-262-2137 (International) Live audio webcast at cticseattle.com will be archived for post listening approximately two hours after call ends, available for five days Call-back numbers for post listening available at 6:30 p.m. Eastern: 1-800-405-2236 (US Participants) 1-303-590-3000 (International) Passcode: 11093505#

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next